Abstract
We clinically evaluated pazufloxacin (PZFX), a new quinolone-carboxylic acid derivatives, in the treatment of various otorhinolaryngological infections.
There were 42 subjects ranging in age from 17 to 79 years (mean age: 48.2 years) including 20 cases with otitis media, 8 with sinusitis, 8 with tonsillitis, 5 with otitis externa, 1 with right postoperative maxillary cyst with infection. PZFX was orally administrated in a dose of 100to 200mg, b.i.d. or t.i.d. for 1 to 14 days.
The clinical efficacy in 30 evaluable cases was excellent in 15 cases, good in 10, fair in 4, poor in 1. The clinical efficacy rate was 83.3%. Bacteriologically, 30 strains were isolated and 24 of them were eradicated. The eradication rate was 80.0%. No adverse reactions were observed except for one case of low-grade nausea and one case of middle-grade rash. No abnormal laboratory findings were observed except for slight elevation of eosinophils in one case but none of the abnormal fluctuations was serious or presented any particular clinical problems.
These results suggest that PZFX is considered to be a useful antimicrobial agent for treatment of many otorhinolaryngological infections.
